PUFAs for preterm babies
Part of Brain & nervous system, Digestive system, Genetic & congenital, Heart & circulation, Infections, Lungs & breathing clinical trials.
This study looks at whether giving polyunsaturated fatty acids (healthy fats) to preterm babies can help their development. If your baby was born between 24 and 36 weeks and admitted within a day of birth, they may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby was born between 24 weeks and 36 weeks of pregnancy
- Baby is admitted to the hospital within 24 hours after birth
- Baby does not have a severe birth defect
- Baby is not already receiving extra PUFAs beyond standard nutrition and breast milk
- Baby is expected to survive during the hospital stay
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving probiotic supplements to extremely preterm newborns helps improve health outcomes. It’s meant for babies born very early, and the results could help guide safer early nutrition and care.
This study tests whether adding a special fat supplement to the feeding of very premature babies can help prevent or reduce lung damage, which is common in babies born early. The supplement is given through a feeding tube.
This study looks at how adding two specific milk fats (DHA and ARA) through enteral feeding affects metabolism in very early preterm infants. It may help researchers understand what these nutrients do in babies born around 25–30 weeks gestation.
This study looks at whether fatty acids from the mother are linked to the risk of retinopathy of prematurity, an eye condition that can affect very premature babies. It involves checking factors related to how the body responds to fatty acids during pregnancy and comparing mothers in different pregnancy situations.
This study tests whether giving probiotics to very premature babies helps their health. It aims to identify which babies benefit most from this treatment.
This trial tests whether giving an omega-3 fat medicine through an IV (along with standard care) improves breathing and blood-flow problems in newborns with congenital diaphragmatic hernia and persistent pulmonary hypertension. It may help reduce strain on the lungs and heart by targeting inflammation and blood-vessel changes.
Hear when a new Necrotizing Enterocolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.